JOHNSON & JOHNSON

Johnson & Johnson’s new partnership with Nanobiotix on the solid‑tumour radiopharmaceutical JNJ‑1900 shows how milestone‑driven licensing can offset looming patent cliffs, offering immediate cash flow, a royalty upside, and a differentiated, value‑b…

Johnson & Johnson’s June 2026 updates reveal a strategic push: adding high‑margin TECNIS EDOF lenses, advancing rare‑disease drug IMAAVY, and solidifying governance, all aimed at boosting revenue, margins and M&A appeal.

Johnson & Johnson’s resilient earnings, strategic oncology focus, and robust free‑cash‑flow make it a top pick for investors seeking stable dividends amid rapid healthcare shifts.

Johnson & Johnson’s $1 billion acquisition of FireFly Bio’s DAC platform boosts its KRAS‑targeted oncology portfolio, accelerates R&D, and upholds a 64‑year dividend growth commitment.

Johnson & Johnson’s $1 billion acquisition of Firefly Bio adds its Firelink degrader‑antibody platform to target KRAS‑driven cancers, boosting J&J’s oncology pipeline and positioning it for next‑generation, tumor‑specific treatments.

Johnson & Johnson’s modest share‑price rise, driven by Capital World Investors’ 9.5 M‑share stake, highlights its stable dividend strategy and innovation focus, bolstering its status as a resilient healthcare cornerstone for institutional invest…

Johnson & Johnson’s recent talc‑litigation win and steady dividend boost protect earnings and fuel a resilient pharma strategy, highlighting how legal success fuels shareholder value and market‑access gains.

Johnson & Johnson wins talc lawsuit, boosting investor confidence and affirming its solid financial footing amid a defensive sector rally.

Johnson & Johnson’s Nipocalimab shows promising Phase 2 results in Sjögren’s and SLE, driving cautious optimism in the stock and signaling a potential breakthrough in autoimmune therapy.

Johnson & Johnson’s nipocalimab shows promising Phase 2 results in SLE and Sjögren’s, using FcRn blockade to lower autoantibodies and improve disease activity while maintaining a safe profile, with Phase 3 studies underway.